Literature DB >> 10231429

Potential role of platelet activating factor in acute renal failure.

J M López-Novoa1.   

Abstract

The clinical condition of acute renal failure (ARF) can be caused by a diverse number of renal injuries, but it is generally characterized by a sharp reduction in the glomerular filtration rate (GFR). A lipid mediator, platelet activating factor (PAF), may be one of the entities responsible for causing the hemodynamic changes in the ARF kidney because it can act as a vasodilator or vasoconstrictor, depending upon its concentration. This review examines the action and mechanisms of PAF in experimental animal models of ischemia and nephrotoxicity, as well as renal failure associated with extrarenal disease. While further research is necessary before extrapolating our current knowledge of PAF into the prevention of renal failure of therapeutic intervention using PAF antagonists in human ARF, there is reasonable evidence to support its role as a mediator of the decrease in GFR characteristic of ARF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231429     DOI: 10.1046/j.1523-1755.1999.00450.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Myeloperoxidase formation of PAF receptor ligands induces PAF receptor-dependent kidney injury during ethanol consumption.

Authors:  Calivarathan Latchoumycandane; Laura E Nagy; Thomas M McIntyre
Journal:  Free Radic Biol Med       Date:  2015-05-21       Impact factor: 7.376

Review 2.  The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction.

Authors:  M Jerkić; S Vojvodić; J M López-Novoa
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 3.  Pathophysiology of acute kidney injury.

Authors:  David P Basile; Melissa D Anderson; Timothy A Sutton
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

4.  Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice.

Authors:  Kent Doi; Koji Okamoto; Kousuke Negishi; Yoshifumi Suzuki; Akihide Nakao; Toshiro Fujita; Akiko Toda; Takehiko Yokomizo; Yoshihiro Kita; Yasuyuki Kihara; Satoshi Ishii; Takao Shimizu; Eisei Noiri
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

5.  Gq-dependent signaling upregulates COX2 in glomerular podocytes.

Authors:  Liming Wang; Patrick J Flannery; Paul B Rosenberg; Timothy A Fields; Robert F Spurney
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

6.  Structurally diverse metal coordination compounds, bearing imidodiphosphinate and diphosphinoamine ligands, as potential inhibitors of the platelet activating factor.

Authors:  Alexandros B Tsoupras; Maria Roulia; Eleftherios Ferentinos; Ioannis Stamatopoulos; Constantinos A Demopoulos; Panayotis Kyritsis
Journal:  Bioinorg Chem Appl       Date:  2010-06-28       Impact factor: 7.778

Review 7.  Renal endothelial dysfunction in acute kidney ischemia reperfusion injury.

Authors:  David P Basile; Mervin C Yoder
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2014

8.  Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis.

Authors:  Liming Wang; Mathew J Ellis; Timothy A Fields; David N Howell; Robert F Spurney
Journal:  Kidney Blood Press Res       Date:  2008-03-27       Impact factor: 2.687

9.  The effect of calcium channel blocker verapamil on gentamicin nephrotoxicity in rats.

Authors:  Nenad Stojiljković; Slavimir Veljković; Dragan Mihailović; Milan Stoiljković; Dragan Radovanović; Pavle Randelović
Journal:  Bosn J Basic Med Sci       Date:  2008-05       Impact factor: 3.363

10.  Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis.

Authors:  Matheus Correa-Costa; Vinicius Andrade-Oliveira; Tarcio T Braga; Angela Castoldi; Cristhiane F Aguiar; Clarice S T Origassa; Andrea C D Rodas; Meire I Hiyane; Denise M A C Malheiros; Francisco J O Rios; Sonia Jancar; Niels O S Câmara
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.